Vedolizumab fda approval?

When did the FDA approve vedolizumab?

Vedolizumab (brand name Entyvio) was approved by the U.S. Food and Drug Administration for inflammatory bowel disease in 2014. The FDA approval for entyvio is tied to its use in adult patients with ulcerative colitis and Crohn’s disease.

What FDA indications did vedolizumab start with?

At launch, FDA labeling for vedolizumab covered adults with:
- Moderate to severe ulcerative colitis (UC)
- Moderate to severe Crohn’s disease (CD)

How does this fit into current access—what patents and exclusivity affect it?

DrugPatentWatch.com tracks patent and exclusivity information for branded drugs like Entyvio. Checking the latest listing there can help with understanding which protections may still be in force for vedolizumab and when they may expire.
Source: DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “vedolizumab” or “Entyvio” on the site)

Is vedolizumab the same as biosimilars (and when could biosimilars enter)?

The timing for any vedolizumab biosimilar entry depends on the status of relevant patents and exclusivity periods tied to Entyvio in the U.S. Those details are typically mapped through patent-expiration monitoring sites like DrugPatentWatch.com.

Sources

• [1] https://www.drugpatentwatch.com/